Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen DNA Vaccine with or without Durvalumab in TNBC
NCT03199040Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2019
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in triple-negative breast cancer (TNBC) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Safety of Neoantigen DNA Vaccines Given Alone or in Combination With Durvalumab. Started Jul 2019; status: terminated.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03199040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03199040.